KR20030068696A - 스탓3 (stat3) 분자 활성화에 의한 줄기세포의 생체내이식생착효율 증가 - Google Patents
스탓3 (stat3) 분자 활성화에 의한 줄기세포의 생체내이식생착효율 증가 Download PDFInfo
- Publication number
- KR20030068696A KR20030068696A KR1020020008272A KR20020008272A KR20030068696A KR 20030068696 A KR20030068696 A KR 20030068696A KR 1020020008272 A KR1020020008272 A KR 1020020008272A KR 20020008272 A KR20020008272 A KR 20020008272A KR 20030068696 A KR20030068696 A KR 20030068696A
- Authority
- KR
- South Korea
- Prior art keywords
- stat3
- stem cells
- transplantation
- cells
- engraftment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 76
- 230000000694 effects Effects 0.000 title claims abstract description 37
- 230000001965 increasing effect Effects 0.000 title claims abstract description 25
- 238000001727 in vivo Methods 0.000 title claims abstract description 23
- 101100311214 Xenopus laevis stat3.1 gene Proteins 0.000 title 1
- 238000002054 transplantation Methods 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 230000035755 proliferation Effects 0.000 claims abstract description 4
- 238000011458 pharmacological treatment Methods 0.000 claims abstract description 3
- 230000005764 inhibitory process Effects 0.000 claims abstract 3
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 53
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 210000001185 bone marrow Anatomy 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 210000004700 fetal blood Anatomy 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940041181 antineoplastic drug Drugs 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 238000006471 dimerization reaction Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000008929 regeneration Effects 0.000 claims description 4
- 238000011069 regeneration method Methods 0.000 claims description 4
- 102000014400 SH2 domains Human genes 0.000 claims description 3
- 108050003452 SH2 domains Proteins 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000026731 phosphorylation Effects 0.000 claims description 3
- 238000006366 phosphorylation reaction Methods 0.000 claims description 3
- 206010059866 Drug resistance Diseases 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims description 2
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 claims description 2
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 claims description 2
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 claims description 2
- 101710137422 Suppressor of cytokine signaling 2 Proteins 0.000 claims description 2
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims 12
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 108010054814 DNA Gyrase Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 210000001612 chondrocyte Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 210000003954 umbilical cord Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 43
- 101150099493 STAT3 gene Proteins 0.000 abstract description 5
- 238000010322 bone marrow transplantation Methods 0.000 abstract description 4
- 208000032839 leukemia Diseases 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 4
- 102000004127 Cytokines Human genes 0.000 abstract description 3
- 108090000695 Cytokines Proteins 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 238000001415 gene therapy Methods 0.000 abstract description 3
- 238000011476 stem cell transplantation Methods 0.000 abstract description 3
- 208000014951 hematologic disease Diseases 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 210000000496 pancreas Anatomy 0.000 abstract description 2
- 230000030833 cell death Effects 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 238000009201 electron therapy Methods 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000033667 organ regeneration Effects 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 40
- 241001430294 unidentified retrovirus Species 0.000 description 10
- 210000004504 adult stem cell Anatomy 0.000 description 8
- 230000001332 colony forming effect Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101710160107 Outer membrane protein A Proteins 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002629 repopulating effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 102100023978 Signal transducer and activator of transcription 2 Human genes 0.000 description 1
- 101150099872 Stat gene Proteins 0.000 description 1
- 102000015215 Stem Cell Factor Human genes 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108700042656 bcl-1 Genes Proteins 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020020008272A KR20030068696A (ko) | 2002-02-15 | 2002-02-15 | 스탓3 (stat3) 분자 활성화에 의한 줄기세포의 생체내이식생착효율 증가 |
| AU2003245073A AU2003245073A1 (en) | 2002-02-15 | 2003-02-17 | Stat3 activated stem cell |
| KR1020047012711A KR101027288B1 (ko) | 2002-02-15 | 2003-02-17 | 스탓3 활성화 줄기세포 |
| PCT/IB2003/000515 WO2003068952A1 (en) | 2002-02-15 | 2003-02-17 | Stat3 activated stem cell |
| JP2003568067A JP4834291B2 (ja) | 2002-02-15 | 2003-02-17 | Ｓｔａｔ３活性化幹細胞 |
| US10/369,053 US7510870B2 (en) | 2002-02-15 | 2003-02-18 | STAT3 activated stem cell |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020020008272A KR20030068696A (ko) | 2002-02-15 | 2002-02-15 | 스탓3 (stat3) 분자 활성화에 의한 줄기세포의 생체내이식생착효율 증가 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20030068696A true KR20030068696A (ko) | 2003-08-25 |
Family
ID=27725746
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020020008272A Pending KR20030068696A (ko) | 2002-02-15 | 2002-02-15 | 스탓3 (stat3) 분자 활성화에 의한 줄기세포의 생체내이식생착효율 증가 |
| KR1020047012711A Expired - Fee Related KR101027288B1 (ko) | 2002-02-15 | 2003-02-17 | 스탓3 활성화 줄기세포 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047012711A Expired - Fee Related KR101027288B1 (ko) | 2002-02-15 | 2003-02-17 | 스탓3 활성화 줄기세포 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7510870B2 (https=) |
| JP (1) | JP4834291B2 (https=) |
| KR (2) | KR20030068696A (https=) |
| AU (1) | AU2003245073A1 (https=) |
| WO (1) | WO2003068952A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101322889B1 (ko) * | 2004-08-16 | 2013-10-30 | 셀리서치 코포레이션 피티이 리미티드 | 제대의 양막으로부터 줄기/전구세포의 추출 |
| US7838503B2 (en) * | 2005-06-15 | 2010-11-23 | Children's Medical Center Corporation | Methods for extending the replicative lifespan of cells |
| WO2007030693A2 (en) * | 2005-09-08 | 2007-03-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for promoting stem cell proliferation and survival |
| AU2008289209A1 (en) * | 2007-08-16 | 2009-02-26 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Methods for promoting stem cell proliferation and survival |
| US8445517B2 (en) | 2009-12-11 | 2013-05-21 | Dana-Farber Cancer Institute | Stat modulators |
| EP2630232A4 (en) * | 2010-10-22 | 2014-04-02 | Biotime Inc | METHOD FOR MODIFYING TRANSCRIPTIONAL REGULATORY NETWORKS IN STEM CELLS |
| WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
| US20190127700A1 (en) * | 2016-04-06 | 2019-05-02 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Technique for Enhancing Stem Cell Regeneration Through Interaction of Vascular Endothelial Cell and Mesenchymal Stem Cell |
| US20210222128A1 (en) * | 2020-01-22 | 2021-07-22 | Massachusetts Institute Of Technology | Inducible tissue constructs and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4645791A (en) * | 1985-06-24 | 1987-02-24 | Ford Motor Company | Environmentally durable elastomer composition with excellent low temperature dynamic properties |
| US6235873B1 (en) * | 1999-07-31 | 2001-05-22 | The Rockefeller University | Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes |
-
2002
- 2002-02-15 KR KR1020020008272A patent/KR20030068696A/ko active Pending
-
2003
- 2003-02-17 KR KR1020047012711A patent/KR101027288B1/ko not_active Expired - Fee Related
- 2003-02-17 AU AU2003245073A patent/AU2003245073A1/en not_active Abandoned
- 2003-02-17 JP JP2003568067A patent/JP4834291B2/ja not_active Expired - Fee Related
- 2003-02-17 WO PCT/IB2003/000515 patent/WO2003068952A1/en not_active Ceased
- 2003-02-18 US US10/369,053 patent/US7510870B2/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| Annu.Rev.Biomed.Eng., Peter W.Zandstra et al., 2001, Vol.3, p.275-305 * |
| Proc.Natl.Acad.Sci.USA, Regina Raz et al., 1999, Vol.96, p.2846-2851 * |
| The EMBO Journal, Takahiko Matsuda et al., 1999, 18(15),p.4261-4269 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20030157711A1 (en) | 2003-08-21 |
| JP2005517404A (ja) | 2005-06-16 |
| KR20040084918A (ko) | 2004-10-06 |
| JP4834291B2 (ja) | 2011-12-14 |
| WO2003068952A1 (en) | 2003-08-21 |
| KR101027288B1 (ko) | 2011-04-06 |
| AU2003245073A1 (en) | 2003-09-04 |
| US7510870B2 (en) | 2009-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7078673B2 (ja) | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 | |
| US7374934B2 (en) | Cell populations and methods of production thereof | |
| Lee et al. | BAF180 regulates cellular senescence and hematopoietic stem cell homeostasis through p21 | |
| EP1447443A1 (en) | Immortalized mesenchymal cells and utilization thereof | |
| JP2023516632A (ja) | 多能性幹細胞からナチュラルキラー細胞を産生するための方法 | |
| JP7538210B2 (ja) | がん細胞療法用のｐ２１発現単球 | |
| US20190352601A1 (en) | Engineering blood vessel cells for transplantation | |
| JP2021165292A (ja) | 造血器腫瘍治療剤、およびスクリーニング方法 | |
| Bahal et al. | Hematopoietic stem cell gene editing rescues B-cell development in X-linked agammaglobulinemia | |
| KR20030068696A (ko) | 스탓3 (stat3) 분자 활성화에 의한 줄기세포의 생체내이식생착효율 증가 | |
| Wiestler et al. | Oncogene complementation in fetal brain transplants | |
| WO2019201629A1 (en) | Nk cells for use with antibodies in cancer therapy | |
| JPWO2014133090A1 (ja) | 脳腫瘍治療のための多能性幹細胞 | |
| US20230212516A1 (en) | Methods for expanding hematopoietic stem cells | |
| Han et al. | Mesenchymal cell reprogramming in experimental MPLW515L mouse model of myelofibrosis | |
| CA2113555A1 (en) | Yolk sac stem cells | |
| Dao | Manipulation of intracellular and extracellular factors controlling the fate of primary human hematopoietic progenitors: A molecular approach toward gene therapy | |
| Anichini et al. | Stem cells research: impact on molecular biology of cancer and prospects for therapy of neoplastic diseases | |
| HK1222890B (zh) | 条件无限增殖化长期干细胞和制备和使用所述细胞的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20020215 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040310 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20040806 Patent event code: PE09021S02D |
|
| PC1204 | Withdrawal of earlier application forming a basis of a priority claim |
Patent event date: 20020215 Comment text: Patent Application Patent event code: PC12041R01I |